198 related articles for article (PubMed ID: 28035066)
21. Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.
Worrall C; Suleymanova N; Crudden C; Trocoli Drakensjö I; Candrea E; Nedelcu D; Takahashi SI; Girnita L; Girnita A
Oncogene; 2017 Jun; 36(23):3274-3286. PubMed ID: 28092675
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract][Full Text] [Related]
23. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.
Koch A; Lang SA; Wild PJ; Gantner S; Mahli A; Spanier G; Berneburg M; Müller M; Bosserhoff AK; Hellerbrand C
Oncotarget; 2015 Oct; 6(32):32748-60. PubMed ID: 26293674
[TBL] [Abstract][Full Text] [Related]
24. Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression.
Shan X; Aziz F; Tian LL; Wang XQ; Yan Q; Liu JW
Int J Oncol; 2015 Apr; 46(4):1667-76. PubMed ID: 25672851
[TBL] [Abstract][Full Text] [Related]
25. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
[TBL] [Abstract][Full Text] [Related]
26. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
Fenouille N; Puissant A; Tichet M; Zimniak G; Abbe P; Mallavialle A; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
Oncogene; 2011 Dec; 30(49):4887-900. PubMed ID: 21685937
[TBL] [Abstract][Full Text] [Related]
27. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
28. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
29. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
Li M; Zhang Z; Hill DL; Wang H; Zhang R
Cancer Res; 2007 Mar; 67(5):1988-96. PubMed ID: 17332326
[TBL] [Abstract][Full Text] [Related]
30. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels.
Li M; Zhang Z; Hill DL; Chen X; Wang H; Zhang R
Cancer Res; 2005 Sep; 65(18):8200-8. PubMed ID: 16166295
[TBL] [Abstract][Full Text] [Related]
31. Casticin Induced Apoptosis in A375.S2 Human Melanoma Cells through the Inhibition of NF-[Formula: see text]B and Mitochondria-Dependent Pathways In Vitro and Inhibited Human Melanoma Xenografts in a Mouse Model In Vivo.
Shiue YW; Lu CC; Hsiao YP; Liao CL; Lin JP; Lai KC; Yu CC; Huang YP; Ho HC; Chung JG
Am J Chin Med; 2016; 44(3):637-61. PubMed ID: 27109154
[TBL] [Abstract][Full Text] [Related]
32. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
[TBL] [Abstract][Full Text] [Related]
33. Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma cells by activating NF-κB.
Xie B; Cao K; Li J; Chen J; Tang J; Chen X; Xia K; Zhou X; Cheng Y; Zhou J; Xie H
Oncotarget; 2016 Dec; 7(49):80765-80782. PubMed ID: 27779100
[TBL] [Abstract][Full Text] [Related]
34. Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth.
Andreu-Pérez P; Hernandez-Losa J; Moliné T; Gil R; Grueso J; Pujol A; Cortés J; Avila MA; Recio JA
BMC Cancer; 2010 Jun; 10():265. PubMed ID: 20529342
[TBL] [Abstract][Full Text] [Related]
35. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
36. miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
[TBL] [Abstract][Full Text] [Related]
37. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
[TBL] [Abstract][Full Text] [Related]
38. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
39. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
40. Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and Ras.
Lo C; Lai TY; Yang JS; Yang JH; Ma YS; Weng SW; Lin HY; Chen HY; Lin JG; Chung JG
Melanoma Res; 2011 Aug; 21(4):267-73. PubMed ID: 21734530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
